


PRODUCT INFORMATION



CBL0137

Item No. 19110

CAS Registry No.: 1197996-80-7
Formal Name: 1,1'-[9-[2-[(1-methylethyl)amino]ethyl]-9H-carbazole-3,6-diyl]bis-ethanone
Synonyms: CBLC137, Curaxin 137
MF: C₂₁H₂₄N₂O₂
FW: 336.4
Purity: ≥95%
UV/Vis.: λ_{max}: 259, 291, 332 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CBL0137 is supplied as a crystalline solid. A stock solution may be made by dissolving the CBL0137 in the solvent of choice, which should be purged with an inert gas. CBL0137 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CBL0137 in ethanol is approximately 2 mg/ml and approximately 5 mg/ml in DMSO and DMF.

CBL0137 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CBL0137 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CBL0137 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CBL0137 is a metabolically stable curaxin that activates p53 with an EC₅₀ value of 0.37 μM and inhibits NF-κB with an EC₅₀ of 0.47 μM.¹ It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death.¹ CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates efficacy of gemcitabine (Item No. 11690) in preclinical models of pancreatic cancer.^{1,2}

References

1. Gasparian, A.V., Burkhart, C.A., Purmal, A.A., *et al.* Curaxins: Anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. *Sci. Transl. Med.* **3(95)**, 95ra74 (2011).
2. Burkhart, C., Fleyshman, D., Kohn, R., *et al.* Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. *Oncotarget* **5(22)**, 11038-11053 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM